Literature DB >> 34111059

Decreases in COVID-19 Cases, Emergency Department Visits, Hospital Admissions, and Deaths Among Older Adults Following the Introduction of COVID-19 Vaccine - United States, September 6, 2020-May 1, 2021.

Athalia Christie1, S Jane Henley1, Linda Mattocks1, Robyn Fernando1, Amy Lansky1, Farida B Ahmad1, Jennifer Adjemian1, Robert N Anderson1, Alison M Binder1, Kelly Carey1, Deborah L Dee1, Taylor Dias1, William M Duck1, Denise M Gaughan1, Brianna Casey Lyons1, A D McNaghten1, Meeyoung M Park1, Hannah Reses1, Loren Rodgers1, Katharina Van Santen1, David Walker1, Michael J Beach1.   

Abstract

Throughout the COVID-19 pandemic, older U.S. adults have been at increased risk for severe COVID-19-associated illness and death (1). On December 14, 2020, the United States began a nationwide vaccination campaign after the Food and Drug Administration's Emergency Use Authorization of Pfizer-BioNTech COVID-19 vaccine. The Advisory Committee on Immunization Practices (ACIP) recommended prioritizing health care personnel and residents of long-term care facilities, followed by essential workers and persons at risk for severe illness, including adults aged ≥65 years, in the early phases of the vaccination program (2). By May 1, 2021, 82%, 63%, and 42% of persons aged ≥65, 50-64, and 18-49 years, respectively, had received ≥1 COVID-19 vaccine dose. CDC calculated the rates of COVID-19 cases, emergency department (ED) visits, hospital admissions, and deaths by age group during November 29-December 12, 2020 (prevaccine) and April 18-May 1, 2021. The rate ratios comparing the oldest age groups (≥70 years for hospital admissions; ≥65 years for other measures) with adults aged 18-49 years were 40%, 59%, 65%, and 66% lower, respectively, in the latter period. These differential declines are likely due, in part, to higher COVID-19 vaccination coverage among older adults, highlighting the potential benefits of rapidly increasing vaccination coverage.

Entities:  

Year:  2021        PMID: 34111059     DOI: 10.15585/mmwr.mm7023e2

Source DB:  PubMed          Journal:  MMWR Morb Mortal Wkly Rep        ISSN: 0149-2195            Impact factor:   17.586


  28 in total

Review 1.  COVID-19-from emerging global threat to ongoing pandemic crisis.

Authors:  Karen B Brust; Vinayika Papineni; Cristie Columbus; Alejandro C Arroliga
Journal:  Proc (Bayl Univ Med Cent)       Date:  2022-05-09

2.  An analysis of the accuracy of COVID-19 country transmission classification.

Authors:  I Deza-Cruz; J M Prada; V Del Rio Vilas
Journal:  Sci Rep       Date:  2022-06-10       Impact factor: 4.996

3.  Immunogenicity and Reactogenicity of the Booster Dose of COVID-19 Vaccines and Related Factors: A Panel Study from the General Population in Serbia.

Authors:  Maja Stosic; Marija Milic; Milos Markovic; Ivana Kelic; Zoran Bukumiric; Marko Veljkovic; Darija Kisic Tepavcevic; Vladan Saponjic; Dragana Plavsa; Sofija Jovanovic; Verica Jovanovic
Journal:  Vaccines (Basel)       Date:  2022-05-25

4.  [Impact of vaccination on admissions to an intensive care unit for COVID-19 in a third-level hospital].

Authors:  A González-Castro; E Cuenca Fito; A Fernandez; R Ferrero Franco; J C Rodríguez Borregán; C Gonzalez
Journal:  Med Intensiva       Date:  2021-08-30       Impact factor: 2.799

5.  Behavioural insights and the evolving COVID-19 pandemic.

Authors:  Marijn de Bruin; Jonathan E Suk; Marianna Baggio; Sarah Earnshaw Blomquist; María Falcon; Maria João Forjaz; Karina Godoy-Ramirez; Mariken Leurs; Carmen Rodriguez-Blazquez; María Romay-Barja; Ellen Uiters; John Kinsman
Journal:  Euro Surveill       Date:  2022-05

6.  Humoral and cellular immunogenicity of SARS-CoV-2 vaccines in chronic lymphocytic leukemia: a prospective cohort study.

Authors:  J Erika Haydu; Jenny S Maron; Robert A Redd; Kathleen M E Gallagher; Stephanie Fischinger; Jeffrey A Barnes; Ephraim P Hochberg; P Connor Johnson; R W Takvorian; Katelin Katsis; Daneal Portman; Jade Ruiters; Sidney Sechio; Mary Devlin; Connor Regan; Kimberly G Blumenthal; Aleena Banerji; Allen D Judd; Krista J Scorsune; Brianne M McGree; Maryanne M Sherburne; Julia M Lynch; James I Weitzman; Matthew Lei; Camille N Kotton; Anand S Dighe; Marcela V Maus; Galit Alter; Jeremy S Abramson; Jacob D Soumerai
Journal:  Blood Adv       Date:  2022-03-22

Review 7.  Multilevel determinants of COVID-19 vaccination hesitancy in the United States: a rapid systematic review.

Authors:  Ying Wang; Yu Liu
Journal:  Prev Med Rep       Date:  2021-12-16

8.  Reactogenicity within 2 weeks after mRNA COVID-19 vaccines: Findings from the CDC v-safe surveillance system.

Authors:  Johanna Chapin-Bardales; Tanya Myers; Julianne Gee; David K Shay; Paige Marquez; James Baggs; Bicheng Zhang; Charles Licata; Tom T Shimabukuro
Journal:  Vaccine       Date:  2021-10-16       Impact factor: 3.641

9.  Return to School and COVID-19 Vaccination for Pediatric Solid Organ Transplant Recipients in the United States: Expert Opinion for 2021-2022.

Authors:  Kevin J Downes; Victoria A Statler; Rachel C Orscheln; Melissa K Cousino; Michael Green; Marian G Michaels; William J Muller; Tanvi S Sharma; Lara A Danziger-Isakov; Monica I Ardura
Journal:  J Pediatric Infect Dis Soc       Date:  2022-02-23       Impact factor: 3.164

10.  High Effectiveness of SARS-CoV-2 Vaccines in Reducing COVID-19-Related Deaths in over 75-Year-Olds, Ceará State, Brazil.

Authors:  Carlos Henrique Alencar; Luciano Pamplona de Góes Cavalcanti; Magda Moura de Almeida; Patrícia Pereira Lima Barbosa; Kellyn Kessiene de Sousa Cavalcante; Déborah Nunes de Melo; Bruno Cavalcante Fales de Brito Alves; Jorg Heukelbach
Journal:  Trop Med Infect Dis       Date:  2021-07-13
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.